Antiviral Treatment May Cure Hepatitis C In 6 Weeks
April 25, 2016
Bristol’s Opdivo Shows Benefits in Cancer Immunotherapy Trial
April 25, 2016
Show all

Interferon Does Not Up Antidepressant Use in MS Population

Although there were previous concerns about interferon contributing to depression, new research shows no correlation between depression and interferon treatment among the multiple sclerosis (MS) population.

No correlation between interferon treatment and antidepressant use was observed in the multiple sclerosis (MS) population, a large-scale study presented at the 68th AAN Annual Meeting reported.

Using Explorys Enterprise Performance Management, a HIPAA-compliant depersonalized clinical database, Matthew M. Mirsky, MS, of the Mellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland Clinic, Cleveland, OH, assessed the association of antidepressant use and disease modifying therapy (DMT) prescribed for multiple sclerosis.

A search of this database, which totals 50 million patients and spans 26 different healthcare systems, “produced a cohort of individuals diagnosed with MS in the past 3 years, on a specific DMT, who were then placed on any antidepressant,” Mirsky noted.

“Additionally, the antidepressant prevalence was tested in the MS population also on the following DMTs: interferon-B1a, interferon-B1b, combined interferon-B as ‘IFN,’ glatiramer acetate, natalizumab, fingolimod, and dimethyl fumarate,” he added. The data were then further analyzed by age and sex.

Read Full Article: Interferon Does Not Up Antidepressant Use in MS Population – MPR

 

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.